Bristol-Myers Squibb (NY:BMY)

60.95 +1.66 (+2.81%)

Delayed Quote Updated: 3:15 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

94 95 Next >

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

March 26, 2026

Check out the companies making headlines yesterday: Robinhood (NASDAQ:HOOD): Financial services company Robinhood (NASDAQ:HOOD) rose by 4.8% on Wednesday aft...

Via StockStory

Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way

March 25, 2026

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors ↗

March 13, 2026

Via Chartmill

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

March 25, 2026

What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after its positive momentum continued...

Via StockStory

Topics Artificial Intelligence

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill. ↗

March 24, 2026

This pair busts the myth of the sector being a desert for income investors.

Via The Motley Fool

Topics Intellectual Property

Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield

March 23, 2026

Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend? ↗

March 23, 2026

The healthcare company has been a top dividend growth stock for years.

Via The Motley Fool

Topics Intellectual Property

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

March 23, 2026

From Bristol Myers Squibb

Via Business Wire

1 High-Yield Dividend Stock That's Too Cheap to Ignore ↗

March 21, 2026

Sometimes "boring" is the way to go.

Via The Motley Fool

Topics Economy Intellectual Property

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

March 20, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

March 19, 2026

From Bristol Myers Squibb

Via Business Wire

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Bristol‑Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash ↗

March 18, 2026

This pharma stock should hold up well if the market tanks.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

READYSTATE Dumps 361,000 Workiva Shares Worth $32 Million ↗

March 17, 2026

This technology firm provides cloud-based compliance and reporting solutions for organizations with complex regulatory needs worldwide.

Via The Motley Fool

Topics Regulatory Compliance

The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump

March 17, 2026

As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17,...

Via MarketMinute

Topics Earnings Economy Initial Public Offering

Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026

March 16, 2026

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Topics ETFs Economy World Trade

1 S&P 500 Stock Worth Your Attention and 2 We Question

March 12, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

March 10, 2026

A handful of the industry's income-generating gems are hiding in plain sight.

Via The Motley Fool

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 09, 2026

From Bristol Myers Squibb

Via Business Wire

Why Bristol Myers Squibb Stock Crushed it in February ↗

March 08, 2026

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.

Via The Motley Fool

Topics Intellectual Property

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 06, 2026

From Bristol Myers Squibb

Via Business Wire

2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗

March 05, 2026

These stocks can be slow-and-steady wealth compounders.

Via The Motley Fool

Topics Intellectual Property

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2026

Via StockStory

Topics Artificial Intelligence Intellectual Property

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

Bristol Myers Squibb Announces Dividend

March 02, 2026

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

94 95 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.